Loading clinical trials...
Loading clinical trials...
A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Conditions
Interventions
Single FT1050 treated UCB unit
Locations
3
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program
Boston, Massachusetts, United States
Ohio State Univeristy Comprehensive Cancer Center
Columbus, Ohio, United States
Start Date
January 1, 2012
Primary Completion Date
October 1, 2013
Completion Date
November 1, 2013
Last Updated
September 12, 2016
NCT07030400
NCT06043011
NCT06528301
NCT03342144
NCT05168930
NCT05346809
Lead Sponsor
Fate Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions